Senseion Therapeutics Inc.
St. Louis, MO
- UEI
- V2KQH21BGKY5
- CAGE
- 8FXG8
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 7241 Forsyth Blvd, St. Louis, MO 63105, USA
- Website
- senseion.com
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Jacaranda Biosciences, Inc. | San Francisco, CA | — |
| Adepthera LLC | Palo Alto, CA | 325412 Pharmaceutical Preparation Manufacturing |
| Max Biopharma, Inc. | Santa Monica, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Ting Therapeutics, Inc. | San Diego, CA | 325412 Pharmaceutical Preparation Manufacturing |
| CRI Biotech, Inc. | Los Altos, CA | — |
About the company
Senseion Therapeutics Inc. is a biotechnology company based in St. Louis, MO that specializes in developing innovative therapies for the treatment of hearing loss and balance disorders. It is a for-profit corporate entity registered to receive federal grant awards from the U.S. government.
Senseion Therapeutics Inc. has received multiple federal grant awards from agencies within the Department of Health and Human Services (HHS), including the National Heart Lung and Blood Institute (NHLBI) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The $323,485 NHLBI award supports research and development of novel therapeutic compounds targeting the LRRC8 protein for improved glycemic control and antithrombotic activity in patients with type 2 diabetes. The $1,981,858 and $2,479,585 NIDDK awards fund the optimization of small molecule modulators targeting the SWELL1-LRRC8 signaling complex for treating type 2 diabetes, obesity, and non-alcoholic steatohepatitis. Across these projects, Senseion aims to develop first-in-class therapeutics that restore SWELL1-LRRC8 signaling across multiple organ systems dysfunctional in metabolic diseases like diabetes. Activities span hit-to-lead optimization, in vitro and in vivo characterization, IND-enabling studies, and potential clinical development of lead compounds.
Quick answers
Is Senseion Therapeutics Inc. registered in SAM.gov?
Yes. Senseion Therapeutics Inc.'s SAM.gov registration is active through September 2, 2027.
What is Senseion Therapeutics Inc.'s most recent federal award?
Senseion Therapeutics Inc.'s most recent federal grant award is Targeting LRRC8 signaling to prevent & treat arterial thrombosis in type 2 diabetes (R44HL169181), from National Heart Lung and Blood Institute (NIH), on September 1, 2023.
On GovTribe
See Senseion Therapeutics Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors